Personalised Risk-directed Clot Prevention For Patients With Cancer
Funder
National Health and Medical Research Council
Funding Amount
$645,205.00
Summary
Blood clots are a leading cause of death among cancer patients, second only to cancer itself. This EL1 program includes clinical and laboratory studies to assess the impact of personalised clot prevention for patients receiving cancer treatments in ambulatory care settings. Laboratory studies and evaluation of outcomes among ‘real-world’ patients with cancers at high risk of developing blood clots, will improve understanding of both clots and cancer, to advance research and clinical practice.
Transforming Approaches To Chronic Disease Prevention In Community Settings
Funder
National Health and Medical Research Council
Funding Amount
$2,738,220.00
Summary
Chronic disease is the leading cause of death in Australia. Research has identified a number of interventions to prevent chronic disease. However, most of these are impractical, difficult to implement and so have little impact in improving community health. In this research program I will generate evidence that is relevant for policy makers and practitioners, identifying effective interventions that can feasibly be delivered, and effective approaches to implement them in community settings.
Improved Early Respiratory Support Of Infants And Children
Funder
National Health and Medical Research Council
Funding Amount
$645,205.00
Summary
Worldwide respiratory disease in children has the highest health care burden on society. Children aged <5 years in particular, are increasing in hospital admissions and to intensive care where the cost is elevated. New ways of oxygen therapy have been studied and shown that we can reduce ICU admission if a therapy known as Nasal High Flow (NHF) therapy is applied earlier in the progression of the disease. Further research is needed in NHF therapy and to improve upon our patient outcomes.